We build
better products
Clinical Development
We are advancing a portfolio of plant-derived drug candidates targeting cancer and immune modulation.
Our lead candidates are currently undergoing preclinical and early-stage clinical evaluation, conducted in collaboration with certified hospital research centers.
Scientific Approach & Rationale
Despite advances in oncology, the 5-year survival rate for aggressive cancers (lung, gastric, pancreatic) remains below 35%. Current therapies often fail due to tumor metabolic plasticity.
Phairilab’s polymolecular approach:
- Combines biodiversity with state-of-the-art pharmacology to delivermulti-target therapeutics.
- Targets tumor metabolism toreduce metastasis.
- Enhances immune system activation.
Science & Pipeline
Integrated Production Model
Unlike conventional biotech, our innovation is powered by vertically integrated sourcing, enabling:
- Controlled and certified cultivation of medicinal plants.
GMP-compliant extraction of Active Pharmaceutical Ingredients (API).
Formulation and manufacturing for capsules, liquids and topical formats.
Nuestras publicaciones
02
03
Phyto-Immunotherapy, a Complementary Therapeutic Option to Decrease Metastasis and Attack Breast Cancer Stem Cells
Leer aquí